Immix Biopharma, Inc. (IMMX)
Nasdaq · Healthcare · Biotechnology
$10.13+4.65%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $840M
- 52-week range
- $2.00 – $15.10
- 52-week change
- +331.18%
- EPS (trailing)
- −$0.88
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 6, 2026
Fiscal year to Dec 2025
- Net income
- −$29.4M
- Diluted EPS
- −$0.89
- Free cash flow
- −$24.7M
From the company’s annual report on SEC EDGAR.
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Headquarters: Los Angeles, United States · 21 employees · immixbio.com